[CAS NO. 1345681-58-4] Vc-seco-DUBA

Name: Vc-seco-DUBA
Brand: Arctom Scientific
SKU: HY-128957

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [1345681-58-4]

Store

Catalog

HY-128957

Brand

MCE

CAS

1345681-58-4

DESCRIPTION [1345681-58-4]

Overview

MDL	-
Molecular Weight	1331.81
Molecular Formula	C65H75ClN12O17
SMILES	O=C(OCC1=CC=C(NC([C@@H](NC([C@@H](NC(OCCOCCN2C(C=CC2=O)=O)=O)C(C)C)=O)CCCNC(N)=O)=O)C=C1)N(C)CCN(C(OC3=CC(N(C[C@H]4CCl)C(C5=CN6C=C(C=CC6=N5)NC(C(C=C7)=CC=C7O)=O)=O)=C4C8=C(C)C=CC=C83)=O)CCOCCO

For research use only. We do not sell to patients.

Summary

Vc-seco-DUBA (SYD985) is a drug-linker conjugate for ADC with potent antitumor activity by using DUBA (DNA alkylating agent), linked via the ADC linker Vc-seco ^[1] .

IC50 & Target

Duocarmycins

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT02277717	Byondis B.V.	Solid Tumors	October 2014	Phase 1
NCT04983238	Byondis B.V.	Metastatic Breast Cancer	January 10, 2022	Phase 1\|Phase 2
NCT04602117	QuantumLeap Healthcare Collaborative\|Byondis B.V.	HER2-positive Breast Cancer\|HER2 Low\|SYD-985\|SYD985\|Vic-trastuzumab Duocarmazine\|Metastatic Cancer\|Metastatic Breast Cancer\|Metastatic Gastrointestinal Carcinoid Tumor\|Metastatic\|HER2 Low Breast Cancer\|GastroEsophageal Cancer\|Gastroesophageal Adenocarcinoma\|Endometrium Tumor\|Ovarian Cancer\|Ovarian Carcinoma\|HER2-positive Gastric Cancer\|HER2-positive Metastatic Breast Cancer\|HER2 Mutation-Related Tumors\|HER-2 Protein Overexpression\|HER2 Low HR Positive\|HR Positive\|Hormone Receptor-positive Breast Cancer\|Estrogen Receptor Positive Tumor\|Progesterone Receptor-positive Breast Cancer\|Triple Negative Breast Cancer\|Hormone Receptor Negative Breast Carcinoma\|Bladder Cancer	July 28, 2021	Phase 1
NCT04235101	Byondis B.V.	Solid Tumor	June 22, 2020	Phase 1
NCT01042379	QuantumLeap Healthcare Collaborative	Breast Neoplasms\|Breast Cancer\|Breast Tumors\|Angiosarcoma\|TNBC - Triple-Negative Breast Cancer\|HER2-positive Breast Cancer\|HER2-negative Breast Cancer\|Hormone Receptor Positive Tumor\|Hormone Receptor Negative Tumor\|Early-stage Breast Cancer\|Locally Advanced Breast Cancer	March 1, 2010	Phase 2
NCT04205630	Byondis B.V.	Endometrial Cancer	May 28, 2020	Phase 2

Appearance

Solid

Shipping

Shipping with dry ice.

Storage

-80°C, protect from light, stored under nitrogen

Solvent & Solubility

In Vitro:

DMSO : 146.67 mg/mL ( 110.13 mM ; ultrasonic and warming and heat to 60°C)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	0.7509 mL	3.7543 mL	7.5086 mL
5 mM	0.1502 mL	0.7509 mL	1.5017 mL
10 mM	0.0751 mL	0.3754 mL	0.7509 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.44 mg/mL (1.83 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: 2.44 mg/mL (1.83 mM); Suspended solution; Need ultrasonic
3.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.44 mg/mL (1.83 mM); Clear solution

* All of the co-solvents are available by MCE.

References

[1] Samantha Congreve, et al. Antibody drug conjugates (ADC) Current status and mapping of ADC:s in clinical programs.